Braizon Therapeutics

Executive Summary

Braizon Therapeutics is a Japanese biotech startup pioneering a glucose-decorated nanocapsule delivery platform designed to transport therapeutic molecules across the blood-brain barrier (BBB). Founded in 2015 and based in Tokyo, the company has raised $10 million in total funding to advance its technology, which aims to enable brain access for both small molecules and biologics. Braizon's platform addresses a critical bottleneck in central nervous system (CNS) drug development—the impermeability of the BBB—and offers potential utility across multiple neurological indications. The company is currently at the preclinical stage, focusing on platform validation and internal pipeline development, while also pursuing licensing opportunities with larger pharmaceutical partners. With a strong scientific premise and a capital-efficient approach, Braizon is positioned to become a key player in CNS drug delivery, though it remains early-stage with no disclosed pipeline candidates.

Upcoming Catalysts (preview)

• Q2 2027Preclinical proof-of-concept data for lead candidate60% success
• Q4 2026First major partnership or licensing deal for platform40% success
• Q3 2026Series B funding round70% success